Drug intelligence / Profile preview

Jiyoutai

Development stage: Phase 3
Lead developer: Jiuyuan Gene Engineering
Modality: Peptides
Administration: Subcutaneous

Overview

**Jiyoutai (JY29-2)** is a biosimilar to Novo Nordisk's Ozempic (semaglutide), developed by Hangzhou Jiuyuan Gene Engineering as an injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA). It mimics the mechanism of semaglutide by binding to and activating the GLP-1 receptor, enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying to improve glycemic control in type 2 diabetes. The drug's new drug application (NDA) was accepted by China's NMPA in April 2024 following a phase 3 trial, positioning it as the first locally developed semaglutide biosimilar in China ahead of Ozempic's patent expiry in 2026.[1][6][7][9]

Brand names: Jiyoutai
Other names: semaglutide biosimilarHangzhou Jiuyuan semaglutide

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on Jiyoutai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiyoutai.

Explore the full profile